nach oben

Clinical & Experimental Metastasis

Erschienen in:

01.12.2011 | Research Paper

Silencing of CD44 by siRNA suppressed invasion, migration and adhesion to matrix, but not secretion of MMPs, of cholangiocarcinoma cells

verfasst von: Pongsanat Pongcharoen, Artit Jinawath, Rutaiwan Tohtong

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

We studied the expression pattern and the role of CD44 in regulating the malignant behavior of two cholangiocarcinoma (CCA) cell lines which expressed different levels of CD44 using the siRNA technique. KKU-100, the high CD44 expresser, exhibited a high degree of in vitro invasiveness, migration and adhesion to Matrigel compared to HuCCA-1. Silencing of CD44 by siRNA did not have a significant effect on cell proliferation. However, in vitro invasiveness, directional migration (chemotaxis) and adhesion to Matrigel were markedly reduced in both cell lines, although chemokinesis and MMP secretion were variable, demonstrating the distinct functional role and requirement for CD44 in different cellular activities and in different cell types. In addition, immunohistochemical analysis suggested that CD44 may be involved in the differentiation process or tumor progression, depending on the macroscopic type of CCA. Taken together, our data indicate that CD44 is an important requirement for the invasive phenotype of CCA cells, although the role that CD44 plays may vary depending on the CCA type and the cellular activity in which it is engaged.

Anderson CD, Pinson CW, Berlin J et al (2004) Diagnosis and treatment of cholangiocarcinoma. Oncologist 9(1):43–57PubMedCrossRef

Gores GJ (2003) Cholangiocarcinoma: current concepts and insights. Hepatology 37(5):961–969PubMedCrossRef

Khan SA, Thomas HC, Davidson BR et al (2005) Cholangiocarcinoma. Lancet 366(9493):1303–1314PubMedCrossRef

Vatanasapt V, Sriamporn S, Vatanasapt P (2002) Cancer control in Thailand. Jpn J Clin Oncol 32(1):S82–S91PubMedCrossRef

Yamasaki S (2003) Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg 10(4):288–291PubMedCrossRef

Yamamoto Y, Shimada K, Sakamoto Y et al (2009) Clinicopathological characteristics of intrahepatic cholangiocellular carcinoma presenting intrahepatic bile duct growth. J Surg Oncol 99(3):161–165PubMedCrossRef

Nakanuma Y, Harada K, Ishikawa A et al (2003) Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 10(4):265–281PubMedCrossRef

Guglielmi A, Ruzzenente A, Campagnaro T et al (2009) Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg 33(6):1247–1254PubMedCrossRef

Zen Y, Fujii T, Itatsu K et al (2006) Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology 44(5):1333–1343PubMedCrossRef

10.

Jinawath N, Chamgramol Y, Furukawa Y et al (2006) Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology 44(4):1025–1038PubMedCrossRef

11.

Pure E, Cuff CA (2001) A crucial role for CD44 in inflammation. Trends Mol Med 7(5):213–221PubMedCrossRef

12.

Goodison S, Urquidi V, Tarin D (1999) CD44 cell adhesion molecules. Mol Pathol 52(4):189–196PubMedCrossRef

13.

Marhaba R, Zoller M (2004) CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35(3):211–231PubMedCrossRef

14.

Underhill C (1992) CD44: the hyaluronan receptor. J Cell Sci 103(2):293–298PubMed

15.

Kittl EM, Haberhauer G, Ruckser R et al (1997) Serum levels of soluble CD44 variant isoforms are elevated in rheumatoid arthritis. Rheumatol Int 16(5):181–186PubMedCrossRef

16.

Lesley J, Hyman R, English N et al (1997) CD44 in inflammation and metastasis. Glycoconj J 14(5):611–622PubMedCrossRef

17.

Ashida K, Terada T, Kitamura Y et al (1998) Expression of E-cadherin, α-catenin, β-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. Hepatology 27(4):974–982PubMedCrossRef

18.

Sato K, Murai H, Ueda Y et al (2006) Intrahepatic sarcomatoid cholangiocarcinoma of round cell variant: a case report and immunohistochemical studies. Virchows Arch 449(5):585–590PubMedCrossRef

19.

Mikami T, Saegusa M, Mitomi H et al (2001) Significant correlations of E-cadherin, catenin, and CD44 variant form expression with carcinoma cell differentiation and prognosis of extrahepatic bile duct carcinomas. Am J Clin Pathol 116(3):369–376PubMedCrossRef

20.

Naor D, Wallach-Dayan SB, Zahalka MA et al (2008) Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 18(4):260–267PubMedCrossRef

21.

Regauer S, Ott A, Berghold A et al (1999) CD44 expression in sinonasal melanomas: is loss of isoform expression associated with advanced tumour stage? J Pathol 187(2):184–190PubMedCrossRef

22.

Aaltomaa S, Lipponen P, Ala-Opas M et al (2001) Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer. Eur Urol 39(2):138–144PubMedCrossRef

23.

Nathan H, Pawlik TM (2010) Staging of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol 26(3):269–273PubMedCrossRef

24.

Bourguignon LY (2008) Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol 18(4):251–259PubMedCrossRef

25.

Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4(1):33–45PubMedCrossRef

26.

Draffin JE, McFarlane S, Hill A et al (2004) CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 64(16):5702–5711PubMedCrossRef

27.

Afify A, Purnell P, Nguyen L (2009) Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol 86(2):95–100PubMedCrossRef

28.

Li CZ, Liu B, Wen ZQ et al (2008) Inhibition of CD44 expression by small interfering RNA to suppress the growth and metastasis of ovarian cancer cells in vitro and in vivo. Folia Biol 54(6):180–186

29.

Torre C, Wang SJ, Xia W et al (2010) Reduction of hyaluronan-CD44-mediated growth, migration, and cisplatin resistance in head and neck cancer due to inhibition of Rho kinase and PI-3 kinase signaling. Arch Otolaryngol Head Neck Surg 136(5):493–501PubMedCrossRef

30.

Alstergren P, Zhu B, Glogauer M et al (2004) Polarization and directed migration of murine neutrophils is dependent on cell surface expression of CD44. Cell Immunol 231(1–2):146–157PubMedCrossRef

31.

Zhu B, Suzuki K, Goldberg HA et al (2004) Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J Cell Physiol 198(1):155–167PubMedCrossRef

32.

Suzuki K, Zhu B, Rittling SR et al (2002) Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts. J Bone Miner Res 17(8):1486–1497PubMedCrossRef

33.

Bourguignon LY, Zhu H, Zhou B et al (2001) Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. J Biol Chem 276(52):48679–48692PubMedCrossRef

34.

Caers J, Gunthert U, De Raeve H et al (2006) The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model. Br J Haematol 132(4):469–477PubMed

35.

Wang SJ, Wreesmann VB, Bourguignon LY (2007) Association of CD44 V3-containing isoforms with tumor cell growth, migration, matrix metalloproteinase expression, and lymph node metastasis in head and neck cancer. Head Neck 29(6):550–558PubMedCrossRef

36.

Weber GF, Ashkar S, Glimcher MJ et al (1996) Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271(5248):509–512PubMedCrossRef

37.

Tzircotis G, Thorne RF, Isacke CM (2005) Chemotaxis towards hyaluronan is dependent on CD44 expression and modulated by cell type variation in CD44-hyaluronan binding. J Cell Sci 118(Pt 21):5119–5128PubMedCrossRef

38.

Yu Q, Stamenkovic I (1999) Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 13(1):35–48PubMedCrossRef

39.

Redondo-Munoz J, Ugarte-Berzal E, Garcia-Marco JA et al (2008) α4β1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 112(1):169–178PubMedCrossRef

40.

Zhang Y, Thant AA, Machida K et al (2002) Hyaluronan-CD44s signaling regulates matrix metalloproteinase-2 secretion in a human lung carcinoma cell line QG90. Cancer Res 62(14):3962–3965PubMed

41.

Takahashi K, Eto H, Tanabe KK (1999) Involvement of CD44 in matrix metalloproteinase-2 regulation in human melanoma cells. Int J Cancer 80(3):387–395PubMedCrossRef

42.

Samanna V, Wei H, Ego-Osuala D et al (2006) α-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells. Exp Cell Res 312(12):2214–2230PubMedCrossRef

43.

Yanagisawa N, Mikami T, Mitomi H et al (2001) CD44 variant overexpression in gallbladder carcinoma associated with tumor dedifferentiation. Cancer 91(2):408–416PubMedCrossRef

44.

Sugino T, Gorham H, Yoshida K et al (1996) Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol 149(3):873–882PubMed

Titel: Silencing of CD44 by siRNA suppressed invasion, migration and adhesion to matrix, but not secretion of MMPs, of cholangiocarcinoma cells
verfasst von: Pongsanat Pongcharoen
Artit Jinawath
Rutaiwan Tohtong
Publikationsdatum: 01.12.2011
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 8/2011
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-011-9414-8

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Silencing of CD44 by siRNA suppressed invasion, migration and adhesion to matrix, but not secretion of MMPs, of cholangiocarcinoma cells

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2011

Interleukin-6 receptor enhances early colonization of the murine omentum by upregulation of a mannose family receptor, LY75, in ovarian tumor cells

Tumor–stromal interactions of the bone microenvironment: in vitro findings and potential in vivo relevance in metastatic lung cancer models

Highly enriched CD133+CD44+ stem-like cells with CD133+CD44high metastatic subset in HCT116 colon cancer cells

Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways

Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver

Reactive oxygen species-mediated PKC and integrin signaling promotes tumor progression of human hepatoma HepG2

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie